Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luisa Ricaurte

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Journal of Neuro-Oncology|September 9, 2021
Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutationAndrés F Cardona, Daniel Jaramillo-Velásquez, Alejandro Ruiz-Patiño, et al.
Thoracic Cancer|December 13, 2019
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP)Alejandro Ruiz-Patiño, Oscar Arrieta, Andrés F Cardona, et al.
Thoracic Cancer|March 17, 2021
Characteristics and outcomes of thymomas in Latin America: Results from over 10 years of experience (CLICaP-LATimus)Claudio Martín, Diego Enrico, Luis Mas, et al.
Biomedica : Revista Del Instituto Nacional De Salud|December 13, 2022
Prognostic significance of telomerase reverse transcriptase promoter gen mutations in high grade meningiomasAlejandro Cañas, Enrique Jiménez, Fernando Hakim, et al.
Cancer Control : Journal of the Moffitt Cancer Center|May 6, 2023
Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing CountryClaudia Cifuentes, Milton Lombana, Henry Vargas, et al.
Targeted Oncology|April 5, 2023
Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort StudyDiego F Chamorro, Andrés F Cardona, July Rodríguez, et al.
Clinical Lung Cancer|July 7, 2022
Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)Andrés F Cardona, Alejandro Ruiz-Patiño, Gonzalo Recondo, et al.
Lung Cancer (Amsterdam, Netherlands)|June 26, 2022
STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)Vladmir C Cordeiro de Lima, Marcelo Corassa, Erick Saldanha, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of Neuro-Oncology|September 9, 2021
Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutationAndrés F Cardona, Daniel Jaramillo-Velásquez, Alejandro Ruiz-Patiño, et al.
Thoracic Cancer|December 13, 2019
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP)Alejandro Ruiz-Patiño, Oscar Arrieta, Andrés F Cardona, et al.
Thoracic Cancer|March 17, 2021
Characteristics and outcomes of thymomas in Latin America: Results from over 10 years of experience (CLICaP-LATimus)Claudio Martín, Diego Enrico, Luis Mas, et al.
Biomedica : Revista Del Instituto Nacional De Salud|December 13, 2022
Prognostic significance of telomerase reverse transcriptase promoter gen mutations in high grade meningiomasAlejandro Cañas, Enrique Jiménez, Fernando Hakim, et al.
Cancer Control : Journal of the Moffitt Cancer Center|May 6, 2023
Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing CountryClaudia Cifuentes, Milton Lombana, Henry Vargas, et al.
Targeted Oncology|April 5, 2023
Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort StudyDiego F Chamorro, Andrés F Cardona, July Rodríguez, et al.
Clinical Lung Cancer|July 7, 2022
Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)Andrés F Cardona, Alejandro Ruiz-Patiño, Gonzalo Recondo, et al.
Lung Cancer (Amsterdam, Netherlands)|June 26, 2022
STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)Vladmir C Cordeiro de Lima, Marcelo Corassa, Erick Saldanha, et al.
Pageof 4